Event Overview

bioLIVE is a global exhibition and content platform that serves as a global hub for both upstream and downstream processing and manufacturing. It connects biotechs, big pharma and service providers including CDMOs and CROs from early stage development to commercial manufacturing and regulatory services. It also features biogeneric and bioinnovator audiences through to manufacturing and laboratory specialists.

bioLIVE runs in parallel to its enormous contract services (ICSE) and small molecule (CPHI Worldwide) exhibitions – both currently the world’s largest in their respective areas – creating natural synergies and establishing the first truly global hub covering the entire biopharma and pharma supply chain.

With the global biopharmaceuticals market estimated to growth of CAGR of 8.6% from 2017 to 2021, to reach an estimated value of US$ 291 billion by 2021 (source: Mordor Intelligence: Global Biopharmaceuticals Market growth, Trends & Forecasts (2017-2022), a number of top trends are emerging, pushing the need for improved productivity and efficiency.

What to expect

The exhibition will be made of 150 exhibitors and will attract over 3000 visitors from across more than 60 countries.

Attendees at bioLIVE will benefit from a mixture of cutting edge science and technology content covering the current trends and challenges in the industry – including presentations and conferences on the latest bio innovations and techniques. A well developed partnering programme will also help attendees be match with the most appropriate business partners making bioLIVE the perfect platform to do business.

 “There is great potential in bringing the bio community together under the auspices of one new global event – running at the same time as CPhI Worldwide. The launch of BioLive will help accelerate the development of the bio supply chain, improve knowledge exchange, and create a more collaborative bio/pharma environment. This new event could provide unique perspectives that can advance the bio industry”

Eric Langer, President and Managing Partner, BioPlan Associates

Exhibitors include companies involved in:

Manufacturing & processing

  • Processing equipment & analytical instruments
  • Bio production, continuous processing, Bio machinery
  • Quality assurance, testing services
  • Cell line, cell culture and fermentation
  • Cell and gene therapy production
  • Technology platforms, automation systems and software
  • Formulation & freeze-drying
  • Analytical development, quality, stability
  • Separation and purification
  • Process control, smart lab design, cleanroom

Biopharma ingredients

Visitors include:

  • Technical buyers (people with a technical background in procurement, sourcing, quality and R&D: principal research scientists, single cell applications engineers, bio analytical business managers)
  • Representatives of biotechs, large and midsize pharmaceutical companies, service providers, specialising in Manufacturing & processing, R&D, Licensing, Procurement and Business development

Copyright © 2017 UBM

Company Information

Find out more about bioLIVE:

9 - 11 October, 2018     IFEMA Madrid

Contract services and R&D

  • CRO, CMO/CDMO, outsourcing
  • R&D, Lab automation and supplies
  • IT & software solutions
  • Cold chain logistics
  • Stem cell research

Commercialised products, vaccines & biosimilars

Insulin, Vaccines, Steriles, Peptides, Injectables, Immunotherapies, ADC

APIs, additives, stabilisers, enzymes, excipients

  • Senior to mid-level executives of biotechs and pharmaceutical companies
  • Researchers from universities and research institutes
  • Wholesalers and distributors, trading companies
  • Professional services & consulting
  • Diagnostics & devices
  • Suppliers & engineering
  • Investors
  • Biomedical Engineering & Equipment Technicians
  • Bio medical & clinical engineers

At the heart of business and innovation in Biopharma


Rutger Oudejans
Brand Director - bioLIVE

Send Rutger an email >>>